Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
⏸️ TMF AMP
ASX 200 Weekly Wrap: ASX retreats as confidence wanes
Share Fallers
These were the worst performing ASX 200 shares last week
Share Fallers
Why Altium, Austal, Challenger, & Mesoblast shares are tumbling lower
Share Market News
Why the Mesoblast share price has soared 310% in the last 3 months
Share Gainers
Why A2 Milk, Afterpay, Mesoblast, and Temple & Webster are pushing higher
Share Gainers
Why Zip Co and these All Ords shares have doubled in 12 months
Share Market News
ASX 200 down 2.2%: Westpac tumbles, TPG reveals special dividend plans
Share Market News
S&P quarterly rebalance: A2 Milk added to ASX 50 & NEXTDC in the ASX 100
Share Market News
Here are all the ASX 200 companies that announced capital raisings in May
⏸️ Investing
2 ASX shares in the fight against coronavirus
Share Fallers
Why Fisher & Paykel Healthcare, Mesoblast, Northern Star, & TechnologyOne are tumbling lower
Share Market News
ASX small-cap sector rallies strongly during April
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
